The NF-κB-antagonistic and p53-agonistic activities of MDM2 inhibitors elicit potent therapeutic effects in experimental lymphoproliferative autoimmune disorders such as SLE and APS (77). Here, NFKB1 is linked to autoimmune polyendocrinopathy.